Literature DB >> 30277494

Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake-Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats.

Asako Namai-Takahashi1,2, Akihiro Sakuyama1, Takahiro Nakamura1, Takahiro Miura1, Junta Takahashi1, Ryo Kurosawa3, Masahiro Kohzuki1, Osamu Ito2.   

Abstract

BACKGROUND: Xanthine oxidase (XO) is a source of reactive oxygen species production in the heart. However, pathophysiological role of XO has not been clarified in hypertensive heart disease. Thus, the present study examined the impacts of high salt (HS) intake and febuxostat (Fx), a XO inhibitor in Dahl salt-sensitive (Dahl-S) rats.
METHODS: Eight-week old, male Dahl-S rats were fed a normal salt diet (0.6% NaCl) or a HS diet (8% NaCl) for 8 weeks. A part of the rats fed the HS diet were simultaneously treated with Fx (3 mg/kg/day).
RESULTS: HS intake increased blood pressure and heart weight with cardiomyocyte hypertrophy and interstitial fibrosis in the left ventricle (LV), and Fx diminished them. HS increased the XO activity 4.7-fold and nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase activity 1.5-fold, and Fx not only blocked the XO activity but also inhibited the HS-increased NADPH oxidase activity. HS increased the expression of XO, collagen, transforming growth factor-β1 (TGF-β1), angiotensin-converting enzyme, and angiotensin II type 1 receptor and the phosphorylation of extracellular signal-regulated kinase (ERK) in the LV, and Fx reduced the expression and phosphorylation of these proteins except XO.
CONCLUSIONS: Fx ameliorates the HS intake-induced hypertension, LV hypertrophy, and fibrosis with decreasing the TGF-β1 expression and ERK phosphorylation in Dahl-S rats. Fx also down-regulates cardiac NADPH oxidase and renin-angiotensin system. The XO inhibition may be an effective therapy for hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30277494     DOI: 10.1093/ajh/hpy143

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension.

Authors:  Brittany Butts; David A Calhoun; Thomas S Denney; Steven G Lloyd; Himanshu Gupta; Krishna K Gaddam; Inmaculada Aban; Suzanne Oparil; Paul W Sanders; Rakesh Patel; James F Collawn; Louis J Dell'Italia
Journal:  Free Radic Biol Med       Date:  2019-01-26       Impact factor: 7.376

2.  NADPH Oxidase Inhibition in Fibrotic Pathologies.

Authors:  Karen Bernard; Victor J Thannickal
Journal:  Antioxid Redox Signal       Date:  2020-03-04       Impact factor: 7.468

3.  Relationship between serum uric acid and clustering of cardiovascular disease risk factors and renal disorders among Shanghai population: a multicentre and cross-sectional study.

Authors:  Min Tao; Xiaoling Pi; Xiaoyan Ma; Yingfeng Shi; Yuzhen Zhang; Hongwei Gu; Yongbin Chi; Shougang Zhuang; Na Liu
Journal:  BMJ Open       Date:  2019-03-01       Impact factor: 2.692

4.  Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.

Authors:  Hiroki Omizo; Yoshifuru Tamura; Chikayuki Morimoto; Masaki Ueno; Yuto Hayama; Emiko Kuribayashi-Okuma; Shunya Uchida; Shigeru Shibata
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.